1-10 of 10
Yihan Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Novel Role of LKB1 in Erythroblast Enucleation

Yuanlin Xu, Jingxin Zhang, Yan Li, Huan Zhang, Peijun Jia, Yazhe Zhen, Wanxin Li, Tingting Zheng, Ying Zhang, Yihan Wang, Yilin Zhang, Yanyan Liu, Xiuli An, Shijie Zhang
Journal: Blood
Blood (2024) 144 (Supplement 1): 539.
https://doi.org/10.1182/blood-2024-209096
Published: 2024
Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Qian Jiang, Li Weiming, Yanli Zhang, Qiang Wang, Suning Chen, Bingcheng Liu, Zhuogang Liu, Jie Jin, Zhenfang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Lie Lin, Wanlin Ye, Shujie Yan, Yihan Wang, Jingrong Cao
Journal: Blood
Blood (2024) 144 (Supplement 1): 477.
https://doi.org/10.1182/blood-2024-205300
Published: 2024
Journal Articles

Tgrx-678 Penetrates Blood-Brain Barrier and Exhibits Preclinical Anti-Tumor Activity in Murine Ph+ CNS Leukemia and ALL Models

Yingying Zuo, Yun Liu, Meng Chen, Yixin Ai, Yanxia Shi, Jingrong Cao, Yihan Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 4176.
https://doi.org/10.1182/blood-2024-199958
Published: 2024
Journal Articles

An Orally Active Pan-BCR::ABL1 Degrader Tgrx-3247 Potently Targets a Wide Spectrum of Orthosteric, Allosteric and Compound Mutations Resistant to TKI Therapies

Yanxia Shi, Fengli He, Li Hu, Nannan Yu, Linxin Li, Cuifang Zheng, Shuzhen Jiang, Tingting Yan, Shuo Zhang, Yinghui Li, Xiangyu Hong, Yun Liu, Yixin Ai, Jiuyang Zhao, Jingrong Cao, Yihan Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 1387.
https://doi.org/10.1182/blood-2024-198975
Published: 2024
Journal Articles

Tgrx-678, a Novel Allosteric Inhibitor of BCR-ABL1, Demonstrates Preclinical Anti-Leukemia Activity, High Oral Bioavailability and Synergism with Ponatinib to Suppress the Highly Resistant Compound Mutations

Yanxia Shi, Qian Jiang, Linxin Li, Shuzhen Jiang, Tingting Yan, Cuifang Zheng, Yixin Ai, Yihan Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 2807.
https://doi.org/10.1182/blood-2023-181391
Published: 2023
Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Qian Jiang, Yanli Zhang, Qiang Wang, Jianyu Weng, Zhenfang Liu, Suning Chen, Li Weiming, Bingcheng Liu, Zhuogang Liu, Yihan Wang, Jingrong Cao
Journal: Blood
Blood (2023) 142 (Supplement 1): 867.
https://doi.org/10.1182/blood-2023-185977
Published: 2023
Journal Articles

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

William C. Shakespeare, PhD, Frank Wang, Ph.D., Qihong Xu, Ph.D., Xiaotian Zhu, Ph.D., Narayana Narasimham, Ph.D., Chester A. Metcalf, Ph.D., Yihan Wang, Ph.D., Raji Sundaramoorthi, Ph.D., Wei-Sheng Huang, Ph.D., Dong Zou, Ph.D., Mathew Thomas, Ph.D., Jan Romero, Ph.D., David Wen, M.S., Ingrid Chen, B.S., Lisi Cai, M.S., Shuangying Liu, M.S., Scott Wardwell, B.S., Yaoyu Ning, M.S., Jeff Keats, B.S., Joseph Snodgrass, Ph.D., Karin Russian, M.S., Marc Broudy, B.S., Thomas O’Hare, Ph.D., Caitlyn Smith, B.S., Amie Corbin, Ph.D., Brian Druker, M.D., John Iuliucci, Ph.D., David Dalgarno, Ph.D., Tomi K. Sawyer, Ph.D., Tim Clackson, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2180.
https://doi.org/10.1182/blood.V108.11.2180.2180
Published: 2006
Journal Articles

Imatinib-Resistant BCR-ABL Mutant Cellular Screening Paradigm To Characterize Promising Small-Molecule Inhibitors: T315I-BCR-ABL Targeted Drug Discovery.

Mohammad Azam, PhD, William C. Shakespeare, PhD, Chester Metcalf, PhD, Yihan Wang, PhD, Raji Sunderamoorthi, PhD, Xiaotan Zhu, PhD, Wei-Sheng Huang, PhD, Dong Zou, PhD, Mathew Thomas, PhD, Jan Romero, PhD, Jeff Keats, PhD, Qihang Xu, PhD, David Dalgarno, PhD, Tim Clackson, PhD, Tomi K. Sawyer, PhD, George Q. Daley, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 2181.
https://doi.org/10.1182/blood.V108.11.2181.2181
Published: 2006
Journal Articles

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit

Amie S. Corbin, Shadmehr Demehri, Ian J. Griswold, Yihan Wang, Chester A. Metcalf, III, Raji Sundaramoorthi, William C. Shakespeare, Joseph Snodgrass, Scott Wardwell, David Dalgarno, John Iuliucci, Tomi K. Sawyer, Michael C. Heinrich, Brian J. Druker, Michael W. N. Deininger
Journal: Blood
Blood (2005) 106 (1): 227–234.
https://doi.org/10.1182/blood-2004-12-4771
Published: 2005
Includes: Supplemental data
Journal Articles

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML

Thomas O'Hare, Roy Pollock, Eric P. Stoffregen, Jeffrey A. Keats, Omar M. Abdullah, Erika M. Moseson, Victor M. Rivera, Hao Tang, Chester A. Metcalf, III, Regine S. Bohacek, Yihan Wang, Raji Sundaramoorthi, William C. Shakespeare, David Dalgarno, Tim Clackson, Tomi K. Sawyer, Michael W. Deininger, Brian J. Druker
Journal: Blood
Blood (2004) 104 (8): 2532–2539.
https://doi.org/10.1182/blood-2004-05-1851
Published: 2004